Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.58 |
| ▸ | PNMT | P11086 | 2/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | IGF1R | P08069 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | AHR | P35869 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | FDPS | P14324 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8494705 | 0.80 | PNMT (0.61) | IDO1PNMTTAAR1SIGMAR1IGF1R | |
| SCHEMBL231954 | 0.79 | IDO1 (0.58) | IDO1PNMTTAAR1SIGMAR1POLB | |
| SCHEMBL20245287 | 0.78 | MAPT (0.41) | IDO1PNMTTAAR1SIGMAR1SLC6A2 | |
| SCHEMBL30123270 | 0.78 | IDO1 (0.37) | IDO1PNMTTAAR1SIGMAR1AHR | |
| SCHEMBL8224395 | 0.78 | TSHR (0.50) | IGF1RALOX15TSHR | |
| SCHEMBL18644044 | 0.78 | IDO1 (0.37) | IDO1PNMTTAAR1SIGMAR1AHR | |
| SCHEMBL3379319 | 0.78 | CYP3A4 (0.68) | IDO1PNMTTAAR1POLBSMN1; SMN2 | |
| SCHEMBL8220202 | 0.78 | PIK3CA (0.44) | IDO1PNMTTAAR1TSHRSLC6A4 | |
| SCHEMBL8368071 | 0.78 | CYP3A4 (0.46) | IDO1PNMTSIGMAR1SLC6A4 | |
| SCHEMBL3298586 | 0.78 | IDO1 (0.64) | IDO1PNMTTAAR1SIGMAR1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023093787-A1 | BENZODIAZEPINE COMPOUND AND APPLICATION THEREOF AS RHO KINASE INHIBITOR | 成都奥睿药业有限公司 | 2023-06-01 | — | — | WO | disclosed |
| WO-2021081677-A1 | CHIRAL GUANIDINES, SALTS THEREOF, METHODS OF MAKING CHIRAL GUANIDINES AND SALTS THEREOF, AND USES OF CHIRAL GUANIDINES AND SALTS THEREOF IN THE PREPARATION OF ENANTIOMERICALLY PURE AMINO ACIDS | FU RUI (CA) | 2021-05-06 | — | — | WO | disclosed |
| CN-111196750-B | Preparation method of benzyl iodide and derivatives thereof | 清华大学 | 2020-11-10 | — | — | CN | disclosed |
| CN-111196750-A | Preparation method of benzyl iodide and derivatives thereof | 清华大学 | 2020-05-26 | — | — | CN | disclosed |
| WO-2020020231-A1 | TWO-QUATERNARY AMMONIUM COMPOUND AND PREPARATION METHOD AND USE THEREOF | 四川大学华西医院 | 2020-01-30 | — | — | WO | disclosed |
| EP-2760856-B1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2016-09-14 | — | — | EP | disclosed |
| EP-2760843-B1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2016-03-02 | — | — | EP | disclosed |
| WO-2013049119-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | WO | disclosed |
| WO-2013048949-A2 | SELECTIVE NR2B ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | WO | disclosed |
| WO-2007137098-A2 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR | KALYPSYS, INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| EP-0485026-A2 | Antimanic phenoxymethylene bisphosphonate derivatives | MERCK SHARP & DOHME LTD. (GB) | 1992-05-13 | — | — | EP | disclosed |
| US-4217362-A | Anilide derivatives as antidepressants | THE UPJOHN COMPANY (US) | 1980-08-12 | — | — | US | disclosed |
| US-4212888-A | Anilide derivatives as antidepressants | THE UPJOHN COMPANY (US) | 1980-07-15 | — | — | US | disclosed |
| US-4128663-A | Anilide derivatives as antidepressants | THE UPJOHN COMPANY (US) | 1978-12-05 | — | — | US | disclosed |